RVNC241220C2500
- 0.60
- 0.000.00%
Revance Therapeutics Newsroom
Revance Therapeutics Is Maintained at Neutral by Mizuho
Revance Therapeutics Analyst Ratings
Express News | Revance Therapeutics Inc : Mizuho Cuts Target Price to $3.10 From $6.66
Mizuho Securities Maintains Revance Therapeutics(RVNC.US) With Hold Rating, Announces Target Price $6.66
Analysts Conflicted on These Healthcare Names: Revance Therapeutics (RVNC), Syndax Pharmaceuticals (SNDX) and Align Tech (ALGN)
12 Health Care Stocks Moving In Monday's Pre-Market Session
Sector Update: Health Care Stocks Edge Higher Monday Afternoon
Analysts' Opinions Are Mixed on These Healthcare Stocks: Artivion (AORT) and Revance Therapeutics (RVNC)
Crown Labs Slashes Revance Therapeutics Takeover Price by 53%
Express News | Revance Therapeutics Shares Fall 20.2% Premarket on Lower-Priced Buyout Offer by Crown Laboratories
Express News | Revance Therapeutics Inc: Crown Will Commence a Tender Offer to Acquire All Outstanding Shares of Revance's Common Stock for $3.10 per Share in Cash
Press Release: Crown Laboratories and Revance Enter Into Amended and Restated Merger Agreement
Crown Laboratories And Revance Enter Into Amended And Restated Merger Agreement >RVNC
Catalyst Watch: Goldman Sachs Finance Conference; Adobe, CostCo Earnings
Revance Therapeutics Extends Tender Offer Deadline For Merger With Crown Laboratories To December 3, 2024 Amid Ongoing Discussions
Express News | Revance Therapeutics Inc - Ongoing Discussions May Result in Further Delays or Modifications to Merger Agreement
Barclays Maintains Revance Therapeutics(RVNC.US) With Hold Rating, Maintains Target Price $7
Barclays Remains a Hold on Revance Therapeutics (RVNC)
Mizuho Securities Maintains Revance Therapeutics(RVNC.US) With Hold Rating
Cautious Hold Rating on Revance Therapeutics Amid Ongoing Merger Uncertainties With Crown Laboratories